{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:51:55Z","timestamp":1783641115417,"version":"3.55.0"},"reference-count":60,"publisher":"CSIRO Publishing","issue":"3","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":3037,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,26]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The aim of screening an asymptomatic population for cancer is to achieve better health outcomes, particularly a population survival benefit. Australia has three population screening programs: the National Cervical Screening Program (NCSP), BreastScreen Australia and the National Bowel Cancer Screening Program (NBCSP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We reviewed the history and development of the three programs.<\/jats:p>\n                    <jats:p>NCSP: Women have a Pap smear every 2 years from age 18\u201320, or 2 years after first becoming sexually active, until age 69. Since introduction of the NCSP, the cervical cancer incidence has halved, with an approximate 60% decrease in mortality. The screening participation rate approximates 57%, but is lower for Aboriginal and Torres Strait Islander women, women in remote areas, and women with lower socio-economic status. The National HPV (human papillomavirus) Vaccination Program, introduced in 2007, is expected to reduce the incidence of cervical cancer by a further 70% and has already reduced the incidence of high-grade lesions in girls. In 2017, testing for HPV every 5 years starting at age 25 will replace the Pap smear as the principal screening test.<\/jats:p>\n                    <jats:p>BreastScreen Australia: This program targets women aged 50\u201374. Over 20 years, mortality from breast cancer has decreased by 32% in response to screening and treatment advances. The participation rate is 56%. The major adverse impact of breast screening is overdiagnosis, estimated in Australia to be as low as 8% of detected cancers, but with estimates of up to 30% from some research. Women should be made aware of both the potential benefits and harms from screening. Genetic testing for BRCA1 and BRCA2 mutations in high-risk women leads to earlier screening.<\/jats:p>\n                    <jats:p>NBCSP: The NBCSP uses immunochemical faecal occult blood test (iFOBT) kits on stool samples to detect bleeding from the bowel. When rollout is complete in 2020, test kits will be sent every 2 years to people aged 50\u201374. People who test positive are followed up with a colonoscopy. The participation rate is currently 37%. The positivity rate is 7%, and stage 1 bowel cancer presentations have tripled since the program began.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Research needs to focus on reducing mortality through increased screening participation and, in the future, obtaining guidance for customised screening from genomic testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.17061\/phrp2731725","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T01:58:30Z","timestamp":1500947910000},"source":"Crossref","is-referenced-by-count":21,"title":["History, development and future of cancer screening in Australia"],"prefix":"10.1071","volume":"27","author":[{"given":"Ian","family":"Olver","sequence":"first","affiliation":[{"name":"A Sansom Institute for Health Research, University of South Australia, Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roder","sequence":"additional","affiliation":[{"name":"B Cancer Epidemiology and Population Health, University of South Australia, Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2017,7,26]]},"reference":[{"key":"2026020117420349400_R1","unstructured":"Wilson JMG, Jungner G. Principles and practices of screening for disease. Geneva: World Health Organization; 1968 [cited 2017 Mar 21]. Available from: apps.who.int\/iris\/handle\/10665\/37650?locale=en&null"},{"key":"2026020117420349400_R2","unstructured":"Australian Government Department of Health. Canberra: Department of Health; 2017. National Cervical Screening Program; 2017 [cited 2017 Mar2] [about 2 screens]. Avalable from: www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/cervical-screening-1"},{"key":"2026020117420349400_R3","unstructured":"Australian Government Department of Health. Canberra: Department of Health; 2017. BreastSceen Australia; 2017 Jul 11 [cited 2017 March 21] [about 2 screens]. Available from: www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/health-professionals-2"},{"key":"2026020117420349400_R4","unstructured":"Australian Government Department of Health. Canberra: Department of Health; 2017. National Bowel Cancer Screening Program; 2017 Mar 1 [cited 2017 Mar 1] [about 2 screens]. Available from: www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/bowel-screening-1"},{"key":"2026020117420349400_R5","unstructured":"Australian Institute of Health and Welfare. Australian incidence and mortality (ACIM). Canberra: AIHW; 2017 [cited 2017 Mar 21]. Available from: aihw.gov.au\/acim-books\/"},{"key":"2026020117420349400_R6","unstructured":"Australian Institute of Health and Welfare. Cervical screening in Australia 2011\u20132012. Canberra: AIHW; 2014 [cited 2017 Mar 21]. Available from: aihw.gov.au\/publication-detail\/?id=60129546865"},{"key":"2026020117420349400_R7","doi-asserted-by":"crossref","unstructured":"Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156(12):880\u201391. CrossRef | PubMed","DOI":"10.7326\/0003-4819-156-12-201206190-00424"},{"key":"2026020117420349400_R8","doi-asserted-by":"crossref","unstructured":"Zhang X, Condon JR, Rumbold AR, Cunningham J, Roder DM. Estimating cancer incidence in Indigenous Australians. Aust N Z J Public Health. 2011;35(5):477\u201385. CrossRef | PubMed","DOI":"10.1111\/j.1753-6405.2011.00762.x"},{"key":"2026020117420349400_R9","unstructured":"Australian Institute of Health and Welfare. Cervical screening in Australia 2012\u20132013. Canberra: AIHW; 2015 [cited 2017 Jul 11]. Available from: www.aihw.gov.au\/publication-detail\/?id=60129550871"},{"key":"2026020117420349400_R10","doi-asserted-by":"crossref","unstructured":"Whop LJ, Garvey G, Baade P, Cunningham J, Lokuge K, Brotherton JM, et al. The first comprehensive report on Indigenous Australian women\u2019s inequalities in cervical screening: a retrospective registry cohort study in Queensland, Australia (2000\u20132011). Cancer. 2016;122(10):1560\u20139. CrossRef | PubMed","DOI":"10.1002\/cncr.29954"},{"key":"2026020117420349400_R11","doi-asserted-by":"crossref","unstructured":"Whop LJ, Baade P, Garvey G, Cunningham J, Brotherton JM, Lokuge K, et al. Cervical abnormalities are more common among Indigenous than other Australian women: a retrospective record-linkage study 2000-2001. PLoS One. 2016;11(4):e.0151473. CrossRef","DOI":"10.1371\/journal.pone.0150473"},{"key":"2026020117420349400_R12","doi-asserted-by":"crossref","unstructured":"Aminisani N, Armstrong B, Canfell K. Uptake of liquid-based cytology as an adjunct to conventional cytology for cervical screening in NSW, Australia: a cross-sectional and population-based cohort analysis. BMC Public Health. 2013;13:1196. CrossRef | PubMed","DOI":"10.1186\/1471-2458-13-1196"},{"key":"2026020117420349400_R13","unstructured":"Australian Government Department of Health. Canberra: Department of Health; 2017. Human Papillomavirus (HPV); 2017 Jan 17 [cited 2017 Jul 11]; [about 3 screens]. Availalble from: health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/immunise-hpv"},{"key":"2026020117420349400_R14","doi-asserted-by":"crossref","unstructured":"International Agency for Research on Cancer Multicenter Cervical Cancer Study Group; Mu\u00f1oz N, Bosch FX, de Sanjos\u00e9 S, Herrero R, Castellsagu\u00e9 X, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518\u201327. CrossRef | PubMed","DOI":"10.1056\/NEJMoa021641"},{"key":"2026020117420349400_R15","doi-asserted-by":"crossref","unstructured":"Garland SM, Ljaer SK, Mu\u00f1oz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519\u201327. CrossRef | PubMed","DOI":"10.1093\/cid\/ciw354"},{"key":"2026020117420349400_R16","doi-asserted-by":"crossref","unstructured":"Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085\u201392. CrossRef | PubMed","DOI":"10.1016\/S0140-6736(11)60551-5"},{"key":"2026020117420349400_R17","doi-asserted-by":"crossref","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372(8):711\u2013723. CrossRef | PubMed","DOI":"10.1056\/NEJMoa1405044"},{"key":"2026020117420349400_R18","doi-asserted-by":"crossref","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383(9916):524\u201332. CrossRef | PubMed","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"2026020117420349400_R19","unstructured":"Compass. Future directions in cervical screening. VCS; 2017. Compass; 2017 [cited 2017 June 1] [about 2 screens]. Available from: www.compasstrial.org.au\/"},{"key":"2026020117420349400_R20","unstructured":"Australian Government Department of Health. Canberra: Department of Health; 2017. National Cervical Screening Program: overview of the renewal; 2017 May 17 [cited 2017 Mar 21] [about 3 screens]. Available from: www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/overview-of-the-renewal"},{"key":"2026020117420349400_R21","unstructured":"Australian Institute of Health and Welfare. Cancer incidence projections: Australia 2011 to 2020. Canberra: AIHW; 2012 [cited 2017 Jul 11]. Available from: www.aihw.gov.au\/publication-detail\/?id=10737421461"},{"key":"2026020117420349400_R22","unstructured":"Australian Institute of Health and Welfare. BreastScreen Australia monitoring report 2010\u20132011. Canberra: AIHW; 2013 [cited 2017 Mar 21]. Available from: www.aihw.gov.au\/publication-detail\/?id=60129544882"},{"key":"2026020117420349400_R23","unstructured":"Roder D. Impact of population screening programs on cancer outcomes. Cancer Forum. 2012;36(1):5\u201310. Article"},{"key":"2026020117420349400_R24","doi-asserted-by":"crossref","unstructured":"Berry DA, Cronin KAS, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784\u201392. CrossRef | PubMed","DOI":"10.1056\/NEJMoa050518"},{"key":"2026020117420349400_R25","doi-asserted-by":"crossref","unstructured":"Morrell S, Taylor R, Roder D, Dobson A. Mammography screening and breast cancer mortality in Australia: an aggregate cohort study. J Med Screen. 2012;19(1):26\u201334. CrossRef | PubMed","DOI":"10.1258\/jms.2012.011127"},{"key":"2026020117420349400_R26","doi-asserted-by":"crossref","unstructured":"Taylor R, Morrell S, Estoesta J, Brassil A. Mammography screening and breast cancer mortality in New South Wales. Cancer Causes Control. 2004;15(6):543\u201350. CrossRef | PubMed","DOI":"10.1023\/B:CACO.0000036153.95908.f2"},{"key":"2026020117420349400_R27","doi-asserted-by":"crossref","unstructured":"Roder D, Houssami N, Farshid G, Gill G, Luke C, Downey P, et al. Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res Treat. 2008;108(3):409\u201316. CrossRef | PubMed","DOI":"10.1007\/s10549-007-9609-5"},{"key":"2026020117420349400_R28","doi-asserted-by":"crossref","unstructured":"Nickson C, Mason KE, English DR, Kavanagh AM. Mammographic screening and breast cancer mortality: a case-control study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1479\u201388. CrossRef | PubMed","DOI":"10.1158\/1055-9965.EPI-12-0468"},{"key":"2026020117420349400_R29","unstructured":"Australian Government Department of Health. Canberra: Department of Health; 2017. BreastScreen Australia; 2014 Oct 24. Program evaluation. BreastScreen Australia final report, 2009 [cited 2017 Mar 21] [about 13 screens]. Available from: cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/programme-evaluation"},{"key":"2026020117420349400_R30","doi-asserted-by":"crossref","unstructured":"Otto SJ, Fracheboud J, Verbeek AL, Boer R, Reijerink-Verheij JC, Otten JD, et al. Mammography screening and risk of breast cancer death: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21(1):66\u201373. CrossRef | PubMed","DOI":"10.1158\/1055-9965.EPI-11-0476"},{"key":"2026020117420349400_R31","doi-asserted-by":"crossref","unstructured":"Njor SH, Olsen AH, Blichert-Toft M, Schwartz W, Vejborg I, Lynge E. Overdiagnosis in screening mammography in Denmark: population based cohort study. BMJ. 2013;346:f1064. CrossRef | PubMed","DOI":"10.1136\/bmj.f1064"},{"key":"2026020117420349400_R32","doi-asserted-by":"crossref","unstructured":"Falk RS, Hofvind S, Skaane P, Haldorsen T. Overdiagnosis among women attending a population-based mammography screening program. Int J Cancer. 2013;133(3):705\u201312. CrossRef | PubMed","DOI":"10.1002\/ijc.28052"},{"key":"2026020117420349400_R33","doi-asserted-by":"crossref","unstructured":"Morrell S, Barratt A, Irwig L, HowardK, Biesheuvel C, Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control. 2010;21(2):275\u201382. CrossRef | PubMed","DOI":"10.1007\/s10552-009-9459-z"},{"key":"2026020117420349400_R34","doi-asserted-by":"crossref","unstructured":"Beckmann K, Duffy SW, Lynch J, Hiller J, Farshid G, Roder D. Estimates of over-diagnosis of breast cancer due to population-based mammography screening in South Australia after adjustment for lead time effects. J Med Screen. 2015;22(3):127\u201335. CrossRef | PubMed","DOI":"10.1177\/0969141315573978"},{"key":"2026020117420349400_R35","doi-asserted-by":"crossref","unstructured":"Ghanouni A, Meisel SF, Hersch J, Waller J, Wardle J, Renzi C. Information on \u201coverdiagnosis\u201d in breast screening on prominent United Kingdom and Australia-oriented health websites. PLoS One. 2016;11(3):e0152279. CrossRef | PubMed","DOI":"10.1371\/journal.pone.0152279"},{"key":"2026020117420349400_R36","doi-asserted-by":"crossref","unstructured":"Parker LM, Rychetnik L, Carter SM. The role of communication in breast cancer screening: a qualitative study with Australian experts. BMC Cancer. 2015;15:741. CrossRef | PubMed","DOI":"10.1186\/s12885-015-1749-0"},{"key":"2026020117420349400_R37","doi-asserted-by":"crossref","unstructured":"Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women\u2019s views on overdiagnosis in breast cancer screening: a qualitative study. BMJ. 2013;346:f158. CrossRef | PubMed","DOI":"10.1136\/bmj.f158"},{"key":"2026020117420349400_R38","doi-asserted-by":"crossref","unstructured":"Waller J, Douglas E, Whitaker KL, Wardle J. Women\u2019s responses to information about overdiagnosis in the UK breast cancer screening programme: a qualitative study. BMJ Open. 2013;3(4):pii:e002703 CrossRef | PubMed","DOI":"10.1136\/bmjopen-2013-002703"},{"key":"2026020117420349400_R39","unstructured":"Medical Services Advisory Committee. Breast magnetic resonance imaging: assessment report. MSAC application 1098. Canberra: Commonwealth of Australia; 2007 [cited 2017 Mar 21]. Available from: www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/A5DC00F5BABA24A9CA25801000123B45\/$File\/1098-Assessment-Report.pdf"},{"key":"2026020117420349400_R40","doi-asserted-by":"crossref","unstructured":"Ahmadloo S, Nakaoka H, Hayano T Hosomichi K, You H, Utsuno E, et al. Rapid and cost-effective high-throughput sequencing for identification of germline mutations of BRCA1 and BRCA2. J Hum Genet. 2017;62(5):561\u20137. CrossRef | PubMed","DOI":"10.1038\/jhg.2017.5"},{"key":"2026020117420349400_R41","doi-asserted-by":"crossref","unstructured":"Vysotskaia VS, Hogan GJ, Gould GM, Wang X, Robertson AD, Haas KR, et al. Development and validation of a 36-gene sequencing assay for hereditary cancer risk assessment. PeerJ. 2017;5:e3046. CrossRef | PubMed","DOI":"10.7717\/peerj.3046"},{"key":"2026020117420349400_R42","doi-asserted-by":"crossref","unstructured":"Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434\u20137. CrossRef | PubMed","DOI":"10.1093\/jnci\/91.5.434"},{"key":"2026020117420349400_R43","unstructured":"Australian Government Department of Health. Canberra: Commonwealth of Australia. National Bowel Cancer Screening Program: overview of the NBCSP; 2017 Jul 12 [cited 2017 Mar 21]; [about 4 screens]. Available from: www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/rev-nbcs-prog-pt2~overview"},{"key":"2026020117420349400_R44","unstructured":"Commonwealth of Australia. Portfolio budget statements 2008-09: budget related paper no. 1.10. Health and ageing portfolio. Canberra: Commonwealth of Australia; 2008 [cited 2017 Mar 21]. Available from: www.health.gov.au\/internet\/budget\/publishing.nsf\/Content\/2008-2009_Health_PBS_sup4\/$File\/Health%20and%20Ageing%20Portfolio%20Budget%20Statements%202008-09.pdf"},{"key":"2026020117420349400_R45","unstructured":"Australian Government Department of Health. Canberra: Commonwealth of Australia. Australian Government 2012-13 health and ageing portfolio budget statements; 2012 May 8 [cited 2017 Mar 21]; [about 4 screens]. Available from: www.health.gov.au\/internet\/budget\/publishing.nsf\/Content\/2012-2013_Health_PBS"},{"key":"2026020117420349400_R46","unstructured":"Australian Government Department of Health. Canberra: Commonwealth of Australia. More bowel cancer screening will save lives; 2014 May 13 [cited 2017 Mar 21]; [about 2 screens]. Available from: www.health.gov.au\/internet\/budget\/publishing.nsf\/content\/budget2014-hmedia09.htm"},{"key":"2026020117420349400_R47","unstructured":"Australian Government Department of Health. Canberra: Commonwealth of Australia. National Bowel Screening Program re-issuing kits to some participants as a precautionary measure; 2016 Feb 15 [cited 2017 Jul 12]; [about 2 screens]. Available from: www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/bowel-kit-reissue"},{"key":"2026020117420349400_R48","unstructured":"Australian Institute of Health and Welfare. National Bowel Cancer Screening Program: monitoring report 2016. Canberra: AIHW; 2016. Available from: www.aihw.gov.au\/WorkArea\/DownloadAsset.aspx?id=60129555864"},{"key":"2026020117420349400_R49","doi-asserted-by":"crossref","unstructured":"Tran B, Keating CL, Ananda SS, Kosmider S, Jones I, Croxford M, et al. Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data. Intern Med J. 2012;42(7):794\u2013800. CrossRef | PubMed","DOI":"10.1111\/j.1445-5994.2011.02585.x"},{"key":"2026020117420349400_R50","doi-asserted-by":"crossref","unstructured":"Ananda SS, McLaughlin SJ, Chen F, Hayes IP, Hunter AA, Skinner IJ, et al. Initial impact of Australia\u2019s National Bowel Cancer Screening Program. Med J Aust. 2009;191(7):378\u201381. PubMed","DOI":"10.5694\/j.1326-5377.2009.tb02843.x"},{"key":"2026020117420349400_R51","doi-asserted-by":"crossref","unstructured":"Pignone MP, Flitcroft KL, Howard K, Trevena LJ, Salkeld GP, St John DJ. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. Med J Aust. 2011;194(4):180\u20135. PubMed","DOI":"10.5694\/j.1326-5377.2011.tb03766.x"},{"key":"2026020117420349400_R52","doi-asserted-by":"crossref","unstructured":"Viiala CH, Zimmerman M, Cullen DJ, Hoffman NE. Complication rates of colonoscopy in an Australian teaching hospital environment. Intern Med J. 2003;33(8):355\u20139. CrossRef | PubMed","DOI":"10.1046\/j.1445-5994.2003.00397.x"},{"key":"2026020117420349400_R53","doi-asserted-by":"crossref","unstructured":"Young GP, Pedersen SK, Dekker E, Cole SR, Osborne JM, Symonds El, et al. Evaluation of a 2-gene (IKZF1 and BCAT1) DNA blood test for detection of colorectal cancer. In: AASLD, AGA, ASGE, SSAT. Digestive Disease Week. 2014 May 3\u20136; Chicago; 2014.","DOI":"10.1016\/S0016-5085(14)60198-0"},{"key":"2026020117420349400_R54","doi-asserted-by":"crossref","unstructured":"Austin H, Henley SJ, King J, Richardson LC, Eheman C. Changes in colorectal cancer incidence rates in young and older adults in the United States: what does it tell us about screening. Cancer Causes Control. 2014;25(2):191\u2013201. CrossRef | PubMed","DOI":"10.1007\/s10552-013-0321-y"},{"key":"2026020117420349400_R55","doi-asserted-by":"crossref","unstructured":"Vatandoust S, Price TJ, Ullah S, Roy AC, Beeke C, Young JP, et al. Metastatic colorectal cancer in young adults: a study from the South Australian population-based registry. Clin Colorectal Cancer. 2016;15(1):32\u20136. CrossRef | PubMed","DOI":"10.1016\/j.clcc.2015.07.005"},{"key":"2026020117420349400_R56","doi-asserted-by":"crossref","unstructured":"Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027\u201335. CrossRef | PubMed","DOI":"10.1016\/S0140-6736(14)60525-0"},{"key":"2026020117420349400_R57","unstructured":"Prostate Cancer Foundation of Australia and Cancer Council Australia. PSA testing and early management of test-detected prostate cancer: clinical practice guidelines. Sydney: Prostate Cancer Foundation of Australia and Cancer Council Australia; 2016 [cited 2017 Mar 21]. Available from: wiki.cancer.org.au\/australiawiki\/images\/1\/1b\/PSA_Testing_and_Early_Management_of_Test-detected_Prostate_Cancer_-_Clinical_practice_guidelines_-_Nov15.pdf"},{"key":"2026020117420349400_R58","doi-asserted-by":"crossref","unstructured":"Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330\u20138. CrossRef | PubMed","DOI":"10.7326\/M13-2771"},{"key":"2026020117420349400_R59","doi-asserted-by":"crossref","unstructured":"National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395\u2013409. CrossRef | PubMed","DOI":"10.1056\/NEJMoa1102873"},{"key":"2026020117420349400_R60","unstructured":"Australian Government Standing Committee on Screening. Position statement: lung cancer screening. Canberra: Commonwealth of Australia; 2015 [cited 2017 Mar 21]. Available from: www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/EA40B7C67280E5C8CA257CEE00012DA1\/$File\/Position%20Statement-%20Lung%20Cancer%20Screening%20using%20Low-Dose%20Computed%20Tomography.pdf"}],"container-title":["Public Health Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/pu\/article-pdf\/doi\/10.17061\/phrp2731725\/1821317\/pu19144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/pu\/article-pdf\/doi\/10.17061\/phrp2731725\/1821317\/pu19144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T22:42:10Z","timestamp":1769985730000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/pu\/article\/27\/3\/e2731725\/265207\/History-development-and-future-of-cancer-screening"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,26]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7,26]]}},"URL":"https:\/\/doi.org\/10.17061\/phrp2731725","relation":{},"ISSN":["2204-2091"],"issn-type":[{"value":"2204-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,26]]},"article-number":"e2731725"}}